symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
ABOS,3.84,-0.930675,619901,222215040,0,3.52-11.31,0.09,"Acumen Pharmaceuticals, Inc.",USD,0001576885,US00509G2093,00509G209,NASDAQ Global Select,NASDAQ,Biotechnology,https://acumenpharm.com,"Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.",Mr. Daniel J. O'Connell M.B.A.,Healthcare,US,39,434 297 1000,427 Park Street,Charlottesville,VA,22902,,0,https://financialmodelingprep.com/image-stock/ABOS.png,2021-07-01,False,False,True,False,False
